Design and Mechanism Study of 6c, a Novel Artesunate Derivatives, for Anti-Hepatocellular Carcinoma.

IF 3.4 3区 医学 Q2 ONCOLOGY Journal of Hepatocellular Carcinoma Pub Date : 2025-01-25 eCollection Date: 2025-01-01 DOI:10.2147/JHC.S490445
Shang-Shang Xiong
{"title":"Design and Mechanism Study of 6c, a Novel Artesunate Derivatives, for Anti-Hepatocellular Carcinoma.","authors":"Shang-Shang Xiong","doi":"10.2147/JHC.S490445","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Artesunate can inhibit the proliferation of various tumor cells and has practical value in developing anti-tumor drugs. However, its biological activity against hepatocellular carcinoma is weak. The efficacy of its anti-tumor effect needs to be improved.</p><p><strong>Methods: </strong>11 compounds of three types were designed and synthesized. Their antitumor activity was detected by MTT assay in vitro and subcutaneous xenograft model in vivo. Then, DCFH-DA probe detection and NAC intervention experiments were used to detect ROS levels. The ferroptosis inhibitor (Liproxstatin-1) was used to study the effect of compound 6c in inducing ferroptosis. Western blot was used to observe the expression of apoptosis-related proteins. The ability of 6c to induce apoptosis was detected by Annexin V-FITC/PI double staining and Hoechst 33342 staining experiment. The effect of 6c on cycle arrest was detected by flow cytometry. Molecular simulations of several hybrids with vascular endothelial growth factor receptor 2 (<i>VEGFR-2</i>) and Transferrin receptor protein 1 (<i>TFR1</i>) were performed using MOE molecular docking software.</p><p><strong>Results: </strong>A series of new artemisinin-4-(4-substituted phenoxy) pyridine derivatives were synthesized and their anticancer activities were tested in three lines of hepatocellular carcinoma (HCC) cells. Among the hybrid hits with anticancer activity, a representative 6c compound increased the reactive oxygen species (ROS) level in hepatocellular carcinoma cells and activated mitochondrial apoptosis and ferroptosis, leading to cell cycle arrest at G2/M phase. Molecular docking shows the binding of 6c compound to oncogenic vascular endothelial growth factor receptor 2 (<i>VEGFR-2</i>) and Transferrin receptor protein 1 (<i>TFR1</i>) that are overexpressed in malignant epithelial tumors.</p><p><strong>Conclusion: </strong>Taken together, our identification of the promising compound 6c may hold developmental potential for therapy of hepatocellular carcinoma.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"12 ","pages":"149-167"},"PeriodicalIF":3.4000,"publicationDate":"2025-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11776411/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S490445","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Artesunate can inhibit the proliferation of various tumor cells and has practical value in developing anti-tumor drugs. However, its biological activity against hepatocellular carcinoma is weak. The efficacy of its anti-tumor effect needs to be improved.

Methods: 11 compounds of three types were designed and synthesized. Their antitumor activity was detected by MTT assay in vitro and subcutaneous xenograft model in vivo. Then, DCFH-DA probe detection and NAC intervention experiments were used to detect ROS levels. The ferroptosis inhibitor (Liproxstatin-1) was used to study the effect of compound 6c in inducing ferroptosis. Western blot was used to observe the expression of apoptosis-related proteins. The ability of 6c to induce apoptosis was detected by Annexin V-FITC/PI double staining and Hoechst 33342 staining experiment. The effect of 6c on cycle arrest was detected by flow cytometry. Molecular simulations of several hybrids with vascular endothelial growth factor receptor 2 (VEGFR-2) and Transferrin receptor protein 1 (TFR1) were performed using MOE molecular docking software.

Results: A series of new artemisinin-4-(4-substituted phenoxy) pyridine derivatives were synthesized and their anticancer activities were tested in three lines of hepatocellular carcinoma (HCC) cells. Among the hybrid hits with anticancer activity, a representative 6c compound increased the reactive oxygen species (ROS) level in hepatocellular carcinoma cells and activated mitochondrial apoptosis and ferroptosis, leading to cell cycle arrest at G2/M phase. Molecular docking shows the binding of 6c compound to oncogenic vascular endothelial growth factor receptor 2 (VEGFR-2) and Transferrin receptor protein 1 (TFR1) that are overexpressed in malignant epithelial tumors.

Conclusion: Taken together, our identification of the promising compound 6c may hold developmental potential for therapy of hepatocellular carcinoma.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
新型青蒿素衍生物6c抗肝细胞癌的设计与机制研究。
目的:青蒿琥酯能抑制多种肿瘤细胞的增殖,在开发抗肿瘤药物方面具有实用价值。但其对肝细胞癌的生物活性较弱。其抗肿瘤效果有待提高。方法:设计合成3类11个化合物。采用体外MTT法和体内皮下异种移植模型检测其抗肿瘤活性。然后采用DCFH-DA探针检测和NAC干预实验检测ROS水平。采用铁下垂抑制剂利普司他汀-1研究化合物6c诱导铁下垂的作用。Western blot检测细胞凋亡相关蛋白的表达。采用Annexin V-FITC/PI双染色和Hoechst 33342染色实验检测6c诱导凋亡的能力。流式细胞术检测6c对周期阻滞的影响。利用MOE分子对接软件对几种血管内皮生长因子受体2 (VEGFR-2)和转铁蛋白受体蛋白1 (TFR1)杂交体进行分子模拟。结果:合成了一系列新的青蒿素-4-(4-取代苯氧基)吡啶衍生物,并在3种肝癌细胞中检测了其抗癌活性。在具有抗癌活性的杂交命中,具有代表性的6c化合物增加了肝癌细胞中的活性氧(ROS)水平,激活线粒体凋亡和铁凋亡,导致细胞周期停滞在G2/M期。分子对接显示6c化合物与恶性上皮肿瘤中过表达的致癌血管内皮生长因子受体2 (VEGFR-2)和转铁蛋白受体蛋白1 (TFR1)结合。结论:综上所述,我们所鉴定的化合物6c可能具有治疗肝细胞癌的发展潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
0.50
自引率
2.40%
发文量
108
审稿时长
16 weeks
期刊最新文献
Mechanistic Research on the Crosstalk Between Macrophage Polarization and Energy Metabolic Reprogramming in Hepatocellular Carcinoma. From Flow Modulation to Resection: First in Human Combination of Liver Venous Deprivation and Balloon-Occluded Chemoembolization (LVD-B-TACE): A Case Report Demonstrating a Novel Sequential Concept. Early Recurrent Hepatocellular Carcinoma with CK19 Positive Receiving Transarterial Chemoembolization After Surgical Resection: A Novel Risk Model Study. Gustave Roussy Immune Score Predicts Outcomes in Hepatocellular Carcinoma Treated with TACE and Immunotherapy. Extent of Embolization as an Independent Prognostic Factor in Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1